Michael Flatley
YOU?
Author Swipe
View article: IMG-102. Radio-pathomic assessment of tumor dynamics following radiotherapy in glioblastoma patients
IMG-102. Radio-pathomic assessment of tumor dynamics following radiotherapy in glioblastoma patients Open
Following initial surgical resection, glioblastoma patients typically receive radiotherapy with adjuvant temozolomide to treat the resection cavity and non-enhancing areas beyond its margin. However, radiotherapy’s impact on traditional im…
View article: Multi-site retrospective analysis of diffusion and perfusion magnetic resonance imaging correlates to glioma characteristics derived from radio-pathomic maps
Multi-site retrospective analysis of diffusion and perfusion magnetic resonance imaging correlates to glioma characteristics derived from radio-pathomic maps Open
Background This study determines the relationship between diffusion and perfusion-based magnetic resonance imaging signatures and radio-pathomic maps of tumor pathology in a large, multi-site cohort. Methods This study included perfusion i…
View article: ANGI-11. SEX DIFFERENCES IN SOX2 GLIOBLASTOMA EXPRESSION OUTSIDE MRI-DEFINED CONTRAST ENHANCEMENT AT AUTOPSY
ANGI-11. SEX DIFFERENCES IN SOX2 GLIOBLASTOMA EXPRESSION OUTSIDE MRI-DEFINED CONTRAST ENHANCEMENT AT AUTOPSY Open
INTRODUCTION Sex-determining region Y-box 2 (SOX2) has recently been used as a marker for pluripotency to identify cellular glioblastoma invasion pathologically. This can be used to identify areas of tumor invasion consisting of sparse ind…
View article: ANGI-12. THE IMPACT OF STANDARD-OF-CARE TREATMENT ON THE RELATIONSHIP BETWEEN CELL DENSITY AND SOX2 POSITIVITY IN GLIOBLASTOMA PATIENTS AT AUTOPSY
ANGI-12. THE IMPACT OF STANDARD-OF-CARE TREATMENT ON THE RELATIONSHIP BETWEEN CELL DENSITY AND SOX2 POSITIVITY IN GLIOBLASTOMA PATIENTS AT AUTOPSY Open
INTRODUCTION Sex-determining region Y-box 2 (SOX2) staining highlights pluripotent cells and provides an early sign of tumor cell invasion in glioblastoma patients. This infiltration can often occur at the single cell level and can occur i…
View article: NIMG-28. DIFFUSION DIFFERENCES IN LOW TO HIGH GRADE GLIOMA TRANSFORMATION
NIMG-28. DIFFUSION DIFFERENCES IN LOW TO HIGH GRADE GLIOMA TRANSFORMATION Open
PURPOSE Apparent diffusion coefficient (ADC) maps offer tremendous insight into cellularity and local tissue environment. Proliferation of tumor cells results in increased local cellularity and cell density, thus impairing the free diffusi…
View article: NIMG-41. ASSOCIATION BETWEEN PERFUSION IMAGING METRICS AND RADIO-PATHOMIC MAPS OF TUMOR PROBABILITY WITHIN AND BEYOND THE CONTRAST-ENHANCING VOLUME IN GLIOMA PATIENTS
NIMG-41. ASSOCIATION BETWEEN PERFUSION IMAGING METRICS AND RADIO-PATHOMIC MAPS OF TUMOR PROBABILITY WITHIN AND BEYOND THE CONTRAST-ENHANCING VOLUME IN GLIOMA PATIENTS Open
Perfusion MRI, using both contrast-based techniques such as dynamic susceptibility imaging (DSC) and non-contrast-based techniques like arterial spin labeling (ASL) have been used to monitor blood flow as a marker of angiogenic glioma pres…
View article: STEM-10. SOX2 POSITIVE, PRESUMED TUMOR INVASION MEASURED WELL BEYOND CONTRAST ENHANCEMENT AND FLAIR HYPERINTENSITY IN BOTH TREATED AND UNTREATED GLIOBLASTOMA PATIENTS ASSESSED AT AUTOPSY
STEM-10. SOX2 POSITIVE, PRESUMED TUMOR INVASION MEASURED WELL BEYOND CONTRAST ENHANCEMENT AND FLAIR HYPERINTENSITY IN BOTH TREATED AND UNTREATED GLIOBLASTOMA PATIENTS ASSESSED AT AUTOPSY Open
In the treatment of glioblastoma (GBM), MRI is used to determine location and extent of cancer. It is poorly understood how far tumor invasion may exist outside of contrast enhancement (CE) and FLAIR hyperintensity (FL). This study identif…
View article: NIMG-43. A 57-YEAR-OLD MALE WITH PRIMARY GLIOBLASTOMA TREATED WITH LASER INTERSTITIAL THERMAL THERAPY: IMAGING AND AUTOPSY FINDINGS
NIMG-43. A 57-YEAR-OLD MALE WITH PRIMARY GLIOBLASTOMA TREATED WITH LASER INTERSTITIAL THERMAL THERAPY: IMAGING AND AUTOPSY FINDINGS Open
INTRODUCTION: Glioblastoma (GBM) is an aggressive primary brain cancer with significant resistance to the current therapeutic approach of chemotherapy and radiotherapy, jointly known as chemoradiation (CRT). Magnetic hyperthermia therapy (…
View article: NIMG-44. RADIOMIC FEATURES OF CONTRAST ENHANCED T1 MRI SEQUENCES PREDICT SURVIVAL IN PRIMARY GLIOBLASTOMA PATIENTS WHO UNDERWENT ADJUVANT RADIATION THERAPY
NIMG-44. RADIOMIC FEATURES OF CONTRAST ENHANCED T1 MRI SEQUENCES PREDICT SURVIVAL IN PRIMARY GLIOBLASTOMA PATIENTS WHO UNDERWENT ADJUVANT RADIATION THERAPY Open
PURPOSE Glioblastoma (GBM) is an aggressive primary brain tumor that is monitored through magnetic resonance imaging (MRI). Radiomic analysis offers valuable insight into better understanding the imaging features of these tumors. We tested…
View article: NIMG-31. AXONS INTERSECTING TUMOR ENHANCEMENT (AXITE) RADIOMICS: A NOVEL PREDICTOR FOR OVERALL SURVIVAL IN GLIOBLASTOMA
NIMG-31. AXONS INTERSECTING TUMOR ENHANCEMENT (AXITE) RADIOMICS: A NOVEL PREDICTOR FOR OVERALL SURVIVAL IN GLIOBLASTOMA Open
AIM The diffuse infiltration of glioblastoma (GBM) along the intricate network of white matter (WM) tracts poses a major challenge. Our aim is to investigate the potential of axons intersecting tumor enhancement (AXITE)-derived radiomic fe…
View article: NIMG-11. AUTOPSY-BASED RADIO-PATHOMIC MAPS OF TISSUE COMPOSITION DELINEATE IDH1 STATS IN GLIOMAS
NIMG-11. AUTOPSY-BASED RADIO-PATHOMIC MAPS OF TISSUE COMPOSITION DELINEATE IDH1 STATS IN GLIOMAS Open
Isocitrate dehydrogenase 1 (IDH1) mutation status is used as an important prognostic marker for gliomas, where IDH1-wildtype patients see shorter survival than patients with an IDH1 mutation. This study uses radio-pathomic maps of cell, ex…
View article: NIMG-35. RADIO-PATHOMIC MAPS OF TUMOR PROBABILITY IDENTIFY GLIOBLASTOMA INVASION BEYOND 5-ALA GUIDED RESECTION MARGINS THAT EVENTUALLY EXHIBIT TUMOR RECURRENCE
NIMG-35. RADIO-PATHOMIC MAPS OF TUMOR PROBABILITY IDENTIFY GLIOBLASTOMA INVASION BEYOND 5-ALA GUIDED RESECTION MARGINS THAT EVENTUALLY EXHIBIT TUMOR RECURRENCE Open
Current standard of care for glioblastoma includes surgery followed by chemotherapy and radiation, with extent of resection strongly correlated with survival. There is a need to improve the detection of tumor invasion beyond traditional im…
View article: NIMG-14. AUTOPSY-BASED RADIO-PATHOMIC MAPS REVEAL DEMOGRAPHIC FACTORS IMPACT THE PRESENCE OF TUMOR OUTSIDE CONTRAST ENHANCEMENT IN GLIOMA PATIENTS
NIMG-14. AUTOPSY-BASED RADIO-PATHOMIC MAPS REVEAL DEMOGRAPHIC FACTORS IMPACT THE PRESENCE OF TUMOR OUTSIDE CONTRAST ENHANCEMENT IN GLIOMA PATIENTS Open
Gliomas are vastly heterogenous tumors with wide-ranging pathological signatures; as such, there is a pressing need to understand how individualized factors affect tumor growth patterns to develop treatment plans and improve prognosis. Thi…
View article: NIMG-68. TEMPORAL CHANGES IN TUMOR COMPOSITION DIFFER ACROSS TUMOR GRADE IN GLIOMA
NIMG-68. TEMPORAL CHANGES IN TUMOR COMPOSITION DIFFER ACROSS TUMOR GRADE IN GLIOMA Open
Gliomas are the most common primary adult brain tumor in the United States and their biological heterogeneity makes it difficult to assess and treat tumor progression over time. This study used conventional MRI tumor segmentations to deter…
View article: PCV VS. LOMUSTINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA
PCV VS. LOMUSTINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA Open
AIMS Almost all patients with glioblastoma relapse after initial treatment. At relapse, chemotherapy using multi-agent PCV (Procarbazine, Lomustine and Vincristine) or single agent Lomustine is often employed. Lomustine is an oral agent, a…